Refine
Has Fulltext
- yes (14)
Is part of the Bibliography
- no (14)
Keywords
- Frieden (3)
- Friedenskonferenz (3)
- MSC (3)
- MSC2013 (3)
- Sicherheitskonferenz (3)
- security conference (3)
- München (2)
- Biomarkers (1)
- CTLA-4 (1)
- CVID (1)
Institute
Rezensionen [2020]
(2020)
Verzeichnis
Einzelrezensionen
148 Bäni Rigler, Petra: Bilderbuch – Lesebuch – Künstlerbuch. Elsa Beskows Ästhetik des Materiellen (Heinz-Jürgen Kliewer)
149 Barilaro, Christina/Oetken, Mareile(Hg.): Erzähl mir vom Tier. Tiere in der Kinderliteratur und in der Natur (Kurt Franz)
151 Bieker, Nadine: Erzählanfänge und Erzählschlüsse im Adoleszenzroman (Astrid Henning-Mohr)
153 Blumesberger, Susanne/Seibert, Ernst (Hg.): Kinderliteratur in Wien um 1800 (Michael Stierstorfer)
154 Brons, Patricia/Nickel, Artur /Nicolai, Matthias (Hg.): Kästneriaden zum 120. Geburtstag (Sabine Planka)
156 Dallmann, Christine/Hartung, Anja/Aigner, Alfons /Buchele, Kai-Thorsten (Hg.): Comics. Interdisziplinäre Perspektiven aus Theorie und Praxis auf ein Stiefkind der Medienpädagogik (Carolin Führer)
157 Darr, Yael: The Nation and the Child. Nation Building in Hebrew Children’s Literature, 1930–1970 (Susanne Blumesberger)
159 Dingelmaier, Theresia: Das Märchen vom Märchen. Eine kultur- und literaturwissenschaftliche Untersuchung des deutschsprachigen jüdischen Volks- und Kindermärchens (Kurt Franz)
161 Field, Hannah: Playing with the Book. Victorian Movable Picture Books and the Child Reader (Petra Bäni Rigler)
163 Gittinger, Kerstin/ Loidl, Sonja (Hg.): Unter Wölfen. Käthe Recheis – Literatur und Politik (Lena Hoffmann)
164 Giuriato, Davide/Hubmann, Philipp/Schildmann, Mareike (Hg.): Kindheit und Literatur. Konzepte – Poetik – Wissen (Ernst Seibert)
166 Glasenapp, Gabriele von/Pecher, Claudia Maria/Anker, Martin (Hg.): Martin Luther und die Reformation in der Kinder- und Jugendliteratur. Beiträge zur literarhistorischen und literarästhetischen Praxis (Roland Issler)
169 Gruner, Elizabeth Rose: Constructing the Adolescent Reader in Contemporary Young Adult Fiction (Thomas Kullmann)
171 Harde, Roxanne/Kokkola, Lydia (Hg.): The Embodied Child. Readings in Children’s Literature and Culture (Thomas Kullmann)
172 Holzen, Aleta-Amirée von: Maskierte Helden. Zur Doppelidentität in Pulp-Novels und Superheldencomics (Maike Paiska)
174 Hubli, Kathrin: Kunstprojekt (Mumin-)Buch. Tove Janssons prozessuale Ästhetik und materielle Transmission (Ben Dammers)
175 Jantzen, Christoph/ Josting, Petra/Ritter, Michael (Hg.): Ästhetik – Leserbezug – Wirkung. Ansprüche an Kinder- und Jugendliteratur im Wandel der Zeit (Nadine Bieker)
177 Jung, Britta C.: Komplexe Lebenswelten – multidirektionale Erinnerungsdiskurse. Jugendliteratur zum Nationalsozialismus, Zweiten Weltkrieg und Holocaust im Spiegel des postmemorialen Wandels (Susanne Blumesberger)
179 Meyer, Christina: Producing Mass Entertainment. The Serial Life of the Yellow Kid (Aleta-Amirée von Holzen)
181 Rox-Helmer, Monika: Der historische Jugendroman als geschichtskulturelle Gattung. Fiktionalisierung von Geschichte und ihr didaktisches Potential (Annette Kliewer)
182 Seidel, Nadine Maria: Adoleszenz, Geschlecht, Identität. Queere Konstruktionen in Romanen nach der Jahrtausendwende (Annette Kliewer)
184 Sonyem, Alain Belmond: Kinder- und Jugendliteratur als Gegendiskurs? Zu Afrikavorstellungen in neueren deutschen und deutschafrikanischen Kinder- und Jugendbüchern (Astrid Henning-Mohr)
186 Sprenger, Karoline: Bertolt Brechts Kinderlyrik. Hintergründe, Analysen und fachdidaktische Perspektiven (Kurt Franz)
188 Uhlig, Bettina/ Lieber, Gabriele/Pieper, Irene (Hg.): Erzählen zwischen Bild und Text (Heinz-Jürgen Kliewer) 190 Van Nahl, Ruth: Jugendkrimis im 21. Jahrhundert. Eine Typologie (Sabine Fuchs)
192 Wietersheim, Annegret von: »Später einmal werde ich es dir erzählen«. Leerstellen in der Kinder- und Jugendliteratur der 1950er Jahre (Susanne Blumesberger)
Rezensionen [2021]
(2021)
Verzeichnis
Einzelrezensionen
146 Benner, Julia/Schneider-Kempf, Barbara/Putjenter, Sigrun (Hg.): Schauplatz der Künste – Bild und Text im Kinderbuch. Festgabe
für Carola Pohlmann zum 60. Geburtstag (Claudia Blei-Hoch)
147 Conrad, Maren (Hg.): Moderne Märchen. Populäre Variationen in jugendkulturellen Literatur- und Medienformaten der Gegenwart (Ernst Seibert)
149 Dettmar, Ute/Roeder, Caroline/Tomkowiak, Ingrid (Hg.): Schnittstellen der Kinder- und Jugendmedienforschung. Aktuelle Positionen und Perspektiven (Nicola König)
151 Dettmar, Ute/Pecher, Claudia Maria/Anker, Martin (Hg.): Bilder zu»Klassikern« (Annette Kliewer)
152 Ewers, Hans-Heino (Hg.): Michael Ende. Zur Aktualität eines Klassikers von internationalem Rang (Thomas Boyken)
154 Frickel, Daniela A. /Kagelmann, Andre/Seidler, Andreas /Glasenapp, Gabriele von (Hg.): Kinder- und Jugendmedien im inklusiven Blick. Analytische und didaktische Perspektiven (Susanne Blumesberger)
156 Gansel, Carsten/Ächtler, Norman/KümmerlingMeibauer, Bettina (Hg.): Erzählen über Kindheit und Jugend in der Gegenwartsliteratur (Nadine Bieker)
158 Giuriato, Davide: Grenzenlose Bestimmbarkeit. Kindheiten in der Literatur der Moderne (Julia Boog-Kaminski)
160 Hodkinson, Owen/ Lovatt, Helen (Hg.): Classical Reception and Children’s Literature. Greece, Rome and Childhood Transformation
(Ludger Scherer)
162 Jantzen, Christoph/Ritter, Alexandra/Ritter, Michel (Hg.): Faszination Zauberwelt. Neue Perspektiven auf die Fantastik in Kinder- und Jugendmedien (Ernst Seibert)
164 Josting, Petra/Kruse, Iris (Hg.): Karen-Susan Fessel. Bielefelder Poet in Residence 2018 (Kirsten Kumschlies)
165 Kalbermatten, Manuela: »The match that lights the fire«. Gesellschaft und Geschlecht in Future-Fiction für Jugendliche (Sabine Planka)
167 Kurwinkel, Tobias /Norrick-Rühl, Corinna/ Schmerheim, Philipp (Hg.): Die Welt im Bild erfassen. Multidisziplinäre Perspektiven auf
das Bilderbuch (Sonja Müller-Carstens)
169 Kurwinkel, Tobias /Schmerheim, Philipp (Hg.): Handbuch Kinder- und Jugendliteratur. Unter Mitarbeit von Stefanie Jakobi
(Thomas Boyken)
171 Lexe, Heidi (Hg.): Time Warp und Taschenuhr. Zeit in der Kinder- und Jugendliteratur (Inger Lison)
173 Lötscher, Christine: Die Alice-Maschine. Figurationen der Unruhe in der Populärkultur (Astrid Henning-Mohr)
175 Marciniak, Katarzyna (Hg.): Chasing Mythical Beasts. The Reception of Ancient Monsters in Children’s and Young Adults’ Culture (Thomas Kullmann)
177 Oetken, Mareile/Vach, Karin/Weinkauff, Gina (Hg.): Klaus Ensikat, Stefanie Harjes, Susanne Janssen. Heidelberger Kinderliteraturgespräche 2017/18 (Heinz-Jürgen und Ursula Kliewer)
179 Schäfer, Iris (Hg.): Zur Ästhetik psychischer Krankheiten in kinder- und jugendliterarischen Medien. Psychoanalytische und tiefenpsychologische Analysen – transdisziplinär erweitert (Kirsten Kumschlies)
180 Stemmann, Anna: Räume der Adoleszenz. Deutschsprachige Jugendliteratur der Gegenwart in topographischer Perspektive (Sabine Planka)
Sammelrezensionen
182 Pugh, Tison: Harry Potter and Beyond. On J. K. Rowling’s Fantasies and Other Fictions Jarazo-Álvarez, Rubén/Alderete-Diez, Pilar (Hg.): Cultural Politics in Harry Potter. Life, Death and the Politics of Fear (Thomas Hardtke)
185 Clermont, Philippe/Henky, Danièle (Hg.):Transmédialités du conte Freeman, Matthew/Rampazzo Gambarato, Renira (Hg.): The Routledge Companion to Transmedia Studies (Ludger Scherer)
Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain incompletely understood, and predictive biomarkers for HMA efficacy are lacking. Here, we show that the bioactive metabolite decitabine triphosphate, but not azacytidine triphosphate, functions as activator and substrate of the triphosphohydrolase SAMHD1 and is subject to SAMHD1-mediated inactivation. Retrospective immunohistochemical analysis of bone marrow specimens from AML patients at diagnosis revealed that SAMHD1 expression in leukemic cells inversely correlates with clinical response to decitabine, but not to azacytidine. SAMHD1 ablation increases the antileukemic activity of decitabine in AML cell lines, primary leukemic blasts, and xenograft models. AML cells acquire resistance to decitabine partly by SAMHD1 up-regulation. Together, our data suggest that SAMHD1 is a biomarker for the stratified use of hypomethylating agents in AML patients and a potential target for the treatment of decitabine-resistant leukemia.
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7 + 3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA).
Patients and methods: Patients with newly diagnosed AML >60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1–3) (IMA) or standard induction therapy with cytarabine (100 mg/m2 continuously days 1–7) plus daunorubicin (45 mg/m2 days 3–5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone.
Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33–45] versus 55% (95% CI: 49–61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513).
Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
Background The connection of the variable part of the heavy chain (VH) and and the variable part of the light chain (VL) by a peptide linker to form a consecutive polypeptide chain (single chain antibody, scFv) was a breakthrough for the functional production of antibody fragments in Escherichia coli. Being double the size of fragment variable (Fv) fragments and requiring assembly of two independent polypeptide chains, functional Fab fragments are usually produced with significantly lower yields in E. coli. An antibody design combining stability and assay compatibility of the fragment antigen binding (Fab) with high level bacterial expression of single chain Fv fragments would be desirable. The desired antibody fragment should be both suitable for expression as soluble antibody in E. coli and antibody phage display. Results Here, we demonstrate that the introduction of a polypeptide linker between the fragment difficult (Fd) and the light chain (LC), resulting in the formation of a single chain Fab fragment (scFab), can lead to improved production of functional molecules. We tested the impact of various linker designs and modifications of the constant regions on both phage display efficiency and the yield of soluble antibody fragments. A scFab variant without cysteins (scFabdeltaC) connecting the constant part 1 of the heavy chain (CH1) and the constant part of the light chain (CL) were best suited for phage display and production of soluble antibody fragments. Beside the expression system E.coli, the new antibody format was also expressed in Pichia pastoris. Monovalent and divalent fragments (DiFabodies) as well as multimers were characterised. Conclusion A new antibody design offers the generation of bivalent Fab derivates for antibody phage display and production of soluble antibody fragments. This antibody format is of particular value for high throughput proteome binder generation projects, due to the avidity effect and the possible use of common standard sera for detection.
Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only.
Background: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimumab-induced AEs have lead to a reduction of morbidity, e.g. due to bowel perforations. However, the spectrum of less common AEs is expanding as ipilimumab is increasingly applied. Stringent recognition and management of AEs will reduce drug-induced morbidity and costs, and thus, positively impact the cost-benefit ratio of the drug. To facilitate timely identification and adequate management data on rare AEs were analyzed at 19 skin cancer centers.
Methods and Findings: Patient files (n = 752) were screened for rare ipilimumab-associated AEs. A total of 120 AEs, some of which were life-threatening or even fatal, were reported and summarized by organ system describing the most instructive cases in detail. Previously unreported AEs like drug rash with eosinophilia and systemic symptoms (DRESS), granulomatous inflammation of the central nervous system, and aseptic meningitis, were documented. Obstacles included patientś delay in reporting symptoms and the differentiation of steroid-induced from ipilimumab-induced AEs under steroid treatment. Importantly, response rate was high in this patient population with tumor regression in 30.9% and a tumor control rate of 61.8% in stage IV melanoma patients despite the fact that some patients received only two of four recommended ipilimumab infusions. This suggests that ipilimumab-induced antitumor responses can have an early onset and that severe autoimmune reactions may reflect overtreatment.
Conclusion: The wide spectrum of ipilimumab-induced AEs demands doctor and patient awareness to reduce morbidity and treatment costs and true ipilimumab success is dictated by both objective tumor responses and controlling severe side effects.
Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1–S126, 2006; or http://www.psoriasis-leitlinie.de).
In-depth analyses of cancer cell proteomes are needed to elucidate oncogenic pathomechanisms, as well as to identify potential drug targets and diagnostic biomarkers. However, methods for quantitative proteomic characterization of patient-derived tumors and in particular their cellular subpopulations are largely lacking. Here we describe an experimental set-up that allows quantitative analysis of proteomes of cancer cell subpopulations derived from either liquid or solid tumors. This is achieved by combining cellular enrichment strategies with quantitative Super-SILAC-based mass spectrometry followed by bioinformatic data analysis. To enrich specific cellular subsets, liquid tumors are first immunophenotyped by flow cytometry followed by FACS-sorting; for solid tumors, laser-capture microdissection is used to purify specific cellular subpopulations. In a second step, proteins are extracted from the purified cells and subsequently combined with a tumor-specific, SILAC-labeled spike-in standard that enables protein quantification. The resulting protein mixture is subjected to either gel electrophoresis or Filter Aided Sample Preparation (FASP) followed by tryptic digestion. Finally, tryptic peptides are analyzed using a hybrid quadrupole-orbitrap mass spectrometer, and the data obtained are processed with bioinformatic software suites including MaxQuant. By means of the workflow presented here, up to 8,000 proteins can be identified and quantified in patient-derived samples, and the resulting protein expression profiles can be compared among patients to identify diagnostic proteomic signatures or potential drug targets.